文献速递妇产影像儿科影像US

妊娠早期母体原发感染后使用伐昔洛韦进行先天性巨细胞病毒感染的二级预防

Secondary prevention of congenital cytomegalovirus infection with valacyclovir following maternal primary infection in early pregnancy.
PubMed 文献 · Ultrasound Obstet Gynecol · 2021-09-13

单中心病例对照研究纳入2009至2020年孕14周前经血清学筛查诊断巨细胞病毒母体原发感染的孕妇,2019年10月起对孕14周前原发感染者提供口服高剂量伐昔洛韦(8g/天)治疗,倾向评分匹配65例治疗者与65例未治疗对照,多元logistic回归显示治疗组胎儿感染率较低(OR 0.318,95%CI 0.120-0.841,P=0.021)。

要点

  • 孕14周前诊断巨细胞病毒母体原发感染者,口服伐昔洛韦8g/天与胎儿感染率降低相关(OR 0.318,95%CI 0.120-0.841,P=0.021)。
  • 胎儿感染评估依据孕17-22周羊膜腔穿刺羊水PCR检测病毒DNA。
  • 1例治疗者用药4周后出现急性肾衰竭,停药5天内缓解。

核心结论

  • 本研究证实,在妊娠早期已建立常规母体血清筛查政策的临床环境中,伐昔洛韦二级预防先天性巨细胞病毒感染具有可接受性、耐受性和获益。

研究设计与样本

  • 单中心病例对照研究,纵向队列2009至2020年孕14周前经血清学筛查(IgM、IgG及IgG亲和力)诊断巨细胞病毒母体原发感染共310例,269例接受羊膜腔穿刺PCR检测;2019年10月起对孕14周前原发感染者提供口服伐昔洛韦8g/天(4g每日两次),65例接受治疗,倾向评分匹配65例未治疗对照(匹配围受孕期感染比例和羊膜腔穿刺孕周);胎儿感染以孕17-22周羊水PCR检测病毒DNA评估。

诊断标准与关键数值

  • 胎儿感染判定依据孕17-22周羊膜腔穿刺羊水PCR检测病毒DNA;伐昔洛韦起始中位孕周12.71周(IQR 10.00-13.86),中位治疗时长35天(IQR 26-54);多元logistic回归示治疗组胎儿感染OR 0.318(95%CI 0.120-0.841),P=0.021。

临床应用与阅片要点

  • 在孕早期常规母体血清筛查流程中,对孕14周前诊断巨细胞病毒母体原发感染者可提供口服伐昔洛韦8g/天进行二级预防;治疗期间需注意急性肾衰竭风险(1例用药4周后发生,停药5天内缓解)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Cytomegalovirus (CMV) maternal primary infection (MPI) in early pregnancy is the main risk factor for congenital CMV (cCMV) infection with long-term sequelae. Our aim was to evaluate, in a single center offering CMV serology screening at 11-14 gestational weeks, secondary prevention of cCMV by administration of high-dosage maternal oral valacyclovir (VACV) in the first trimester of pregnancy.

METHODS: This was a case-control study in a longitudinal cohort of pregnancies with CMV-MPI diagnosed prior to 14 weeks of gestation by serology screening (immunoglobulin (Ig) M and IgG measurement and IgG avidity) between 2009 and 2020. From October 2019 onwards, all women presenting at our center with MPI before 14 weeks' gestation were offered treatment with high-dosage oral VACV (8 g/day, 4 g twice/day). We used propensity score matching to compare fetal infection rates in cases treated with maternal oral VACV (8 g/day) with those in untreated controls. Fetal infection was assessed following amniocentesis at 17-22 weeks of gestation, by polymerase chain reaction (PCR) analysis of amniotic fluid for viral DNA.

RESULTS: Of 310 cases of CMV-MPI identified, 269 underwent amniocentesis for PCR. Of these, 66 were offered, and 65 accepted, treatment with VACV. From the remaining untreated cases, we selected 65 controls, matched for proportion of periconceptional infections and gestational age at amniocentesis. VACV was initiated at a median gestational age of 12.71 (interquartile range (IQR), 10.00-13.86) weeks and the median duration of treatment was 35 (IQR, 26-54) days. On multivariate logistic regression, fetal infection was lower in the treated group (odds ratio, 0.318 (95% CI, 0.120-0.841); P = 0.021). One treated patient developed acute renal failure 4 weeks after initiation of VACV therapy, but this resolved within 5 days after treatment was stopped.

CONCLUSION: This study confirms the acceptability, tolerance and benefit of secondary prevention by VACV of cCMV infection in a clinical setting with a well-established routine maternal serum screening policy in the first trimester of pregnancy. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Faure-Bardon V, Fourgeaud J, Stirnemann J, et al. Secondary prevention of congenital cytomegalovirus infection with valacyclovir following maternal primary infection in early pregnancy. Ultrasound Obstet Gynecol. 2021. PMID: 33998084. doi:10.1002/uog.23685

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。